Laplace Interventional Closes Financing for Development of Transcatheter Tricuspid Valve Technology

July 24, 2023—Laplace Interventional, a Minnesota-based medical device company developing a transcatheter tricuspid valve technology, announced that it has completed its first close on a Series B financing round of $12.9 million financing. The proceeds will fund the company’s efforts to achieve early clinical milestones including the first-in-human and clinical feasibility evaluation of its transcatheter prosthetic valve system for patients with tricuspid regurgitation.

Laplace Interventional advised that the device is in the early stage of its development phase and is not approved or cleared by the FDA or any other regulatory body in the world.

The financing was led by ShangBay Capital along with Features Capital. Other participants included Engage Venture Partners, JWC Ventures, and a global strategic investor.

The company also announced that Jenny Barba, cofounder and managing partner at Features Capital, and Todd Mortier, a serial medtech entrepreneur, joined its board of directors.

Ramji Iyer, founder and CEO of Laplace Interventional, stated in the press release, “Our team at Laplace has demonstrated feasibility of our technology in a preclinical setting and we are well positioned to execute our clinical feasibility evaluation in the near future. We are grateful for the validation of our progress from our new and existing investors. We remain laser-focused on our mission of improving the standard of care for patients suffering from tricuspid regurgitation.”